Project description:This SuperSeries is composed of the following subset Series:; GSE15389: Peripheral blood mononuclear cells treated with a CDK inhibitor; GSE15392: DU145 tumor cells treated with a CDK inhibitor; GSE15395: HCT116 tumor cells treated with a CDK inhibitor Experiment Overall Design: Refer to individual Series
Project description:Genome-Scale draft model for Human Peripheral Blood Mononuclear Cells (PBMCs). A GEM for PBMCs was developed by applying the INIT
algorithm on Human Metabolic Reconstruction (HMR 2.0) as a template model. GEMs were contextualised/ constrained for different conditions using expression datasets. The gene/transcript expression data obtained from PBMCs of Type 1 Diabetes progressors, non-progressors, and healthy controls were employed to score each reaction of HMR 2.0. For further detail please refer to Electronic Supplementary Information of Sen et.al, Metabolic alterations in immune cells associate with progression to type 1 diabetes, Diabetologia, 15/01/2020, (https://doi.org/10.1007/s00125-020-05107-6).
Project description:To investigate differential protein and phospho-protein changes in the signaling cascades related to mutant G2019S LRRK2 using peripheral blood mononuclear cells (PBMCs)
Project description:We report RNA-sequencing analysis of human peripheral blood mononuclear cells exposed to clinically recommended doses (500 nM) of the HSP90 inhibitor ganetispib. Global analysis of the expression profiles of treated cells revealed wide spread changes in gene expression, specifically, upregulation of protein folding and assembly pathways, with downregulation of antigen presentation through MHC Class I and Class I.